DrugPatentWatch Database Preview
Drugs in Development Information for CRLX101
» See Plans and Pricing
What is the drug development status for CRLX101?
CRLX101 is an investigational drug.
There have been 12 clinical trials for CRLX101.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2012.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are Cerulean Pharma Inc., National Cancer Institute (NCI), and University of Chicago.
There are sixty-one US patents protecting this investigational drug and five hundred and thirty-five international patents.
Summary for CRLX101
| US Patents | 61 |
| International Patents | 535 |
| US Patent Applications | 147 |
| WIPO Patent Applications | 105 |
| Japanese Patent Applications | 78 |
| Clinical Trial Progress | Phase 2 (2012-04-01) |
| Vendors | 12 |
Recent Clinical Trials for CRLX101
| Title | Sponsor | Phase |
|---|---|---|
| Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | National Cancer Institute (NCI) | Phase 2 |
| Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer | National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Alternative Dosing for CRLX101 Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | Cerulean Pharma Inc. | Phase 1 |
Clinical Trial Summary for CRLX101
Top disease conditions for CRLX101
Top clinical trial sponsors for CRLX101
US Patents for CRLX101
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CRLX101 | Start Trial | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (Brentford, Middlesex, GB) | Start Trial |
| CRLX101 | Start Trial | Benzimidazole derivatives as PI3 kinase inhibitors | GlaxoSmithKline LLC (Wilmington, DE) | Start Trial |
| CRLX101 | Start Trial | ICOS binding proteins | GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB) | Start Trial |
| CRLX101 | Start Trial | Benzimidazole derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (Wilmington, DE) | Start Trial |
| CRLX101 | Start Trial | Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives | Research Triangle Institute (Research Triangle Park, NC) | Start Trial |
| CRLX101 | Start Trial | 10,11-methylenedioxy camptothecins | Research Triangle Institute (Research Triangle Park, NC) | Start Trial |
| CRLX101 | Start Trial | Preparation of water soluble camptothecin derivatives | Glaxo Inc. (Research Triangle Park, NC) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CRLX101
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CRLX101 | Australia | AU2012236868 | 2031-03-25 | Start Trial |
| CRLX101 | Brazil | BR112013024502 | 2031-03-25 | Start Trial |
| CRLX101 | Canada | CA2831143 | 2031-03-25 | Start Trial |
| CRLX101 | Chile | CL2013002737 | 2031-03-25 | Start Trial |
| CRLX101 | China | CN103857393 | 2031-03-25 | Start Trial |
| CRLX101 | Colombia | CO6771447 | 2031-03-25 | Start Trial |
| CRLX101 | Costa Rica | CR20130550 | 2031-03-25 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
